BR112012010502A2 - derivados de benzimidazol-imidazol - Google Patents
derivados de benzimidazol-imidazolInfo
- Publication number
- BR112012010502A2 BR112012010502A2 BR112012010502A BR112012010502A BR112012010502A2 BR 112012010502 A2 BR112012010502 A2 BR 112012010502A2 BR 112012010502 A BR112012010502 A BR 112012010502A BR 112012010502 A BR112012010502 A BR 112012010502A BR 112012010502 A2 BR112012010502 A2 BR 112012010502A2
- Authority
- BR
- Brazil
- Prior art keywords
- imidazole derivatives
- benzimidazole imidazole
- benzimidazole
- derivatives
- imidazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09175015 | 2009-11-04 | ||
EP10154583 | 2010-02-24 | ||
PCT/EP2010/066668 WO2011054834A1 (en) | 2009-11-04 | 2010-11-03 | Benzimidazole-imidazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012010502A2 true BR112012010502A2 (pt) | 2016-03-15 |
Family
ID=43266424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012010502A BR112012010502A2 (pt) | 2009-11-04 | 2010-11-03 | derivados de benzimidazol-imidazol |
Country Status (22)
Country | Link |
---|---|
US (3) | US9427428B2 (pt) |
EP (1) | EP2496572A1 (pt) |
JP (1) | JP6005515B2 (pt) |
KR (1) | KR20120091292A (pt) |
CN (1) | CN102741241B (pt) |
AP (1) | AP2012006216A0 (pt) |
AR (1) | AR078888A1 (pt) |
AU (1) | AU2010317085A1 (pt) |
BR (1) | BR112012010502A2 (pt) |
CA (1) | CA2780034C (pt) |
CL (1) | CL2012001176A1 (pt) |
CO (1) | CO6531445A2 (pt) |
CR (1) | CR20120302A (pt) |
EA (1) | EA022839B1 (pt) |
EC (1) | ECSP12011867A (pt) |
IL (1) | IL219087A0 (pt) |
MX (1) | MX2012005178A (pt) |
TW (1) | TW201127378A (pt) |
UA (1) | UA108211C2 (pt) |
UY (1) | UY32997A (pt) |
WO (1) | WO2011054834A1 (pt) |
ZA (1) | ZA201203205B (pt) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
EP2367824B1 (en) | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Anti-viral derivatives of pyrimidine |
CN102245604A (zh) | 2008-12-23 | 2011-11-16 | 雅培制药有限公司 | 抗病毒化合物 |
US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2011008982A (es) | 2009-02-27 | 2011-09-15 | Enata Pharmaceuticals Inc | Inhibidores del virus de la hepatitis c. |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2011010905A (es) | 2009-04-15 | 2011-11-01 | Abbott Lab | Compuestos antivirales. |
EP2857394A1 (en) | 2009-05-13 | 2015-04-08 | Gilead Pharmasset LLC | Antiviral compounds |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2337781B1 (en) | 2009-06-11 | 2014-07-23 | AbbVie Bahamas Ltd. | Anti-viral compounds to treat hcv infection |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
US20110274648A1 (en) * | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EA201201031A1 (ru) | 2010-01-25 | 2013-02-28 | Энанта Фармасьютиклз, Инк. | Ингибиторы вируса гепатита с |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US9127021B2 (en) | 2010-04-09 | 2015-09-08 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
EP2603080A4 (en) | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2012154321A1 (en) * | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
RU2014131017A (ru) | 2011-12-28 | 2016-02-20 | ЯНССЕН Ар ЭНД Ди АЙРЛЭНД | Хиназолиноновые производные в качестве ингибиторов hcv |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AR093738A1 (es) * | 2012-02-13 | 2015-06-24 | Presidio Pharmaceuticals Inc | Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos |
CN102796084A (zh) * | 2012-09-10 | 2012-11-28 | 合肥科尚医药科技有限公司 | 一种活性物质及其在治疗丙型肝炎中的应用及制备方法 |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
JP6612857B2 (ja) * | 2014-06-03 | 2019-11-27 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ | ベンゾイミダゾールアナログおよび関連方法 |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN116462622B (zh) * | 2023-03-10 | 2024-02-09 | 上海药坦药物研究开发有限公司 | 一种N-Boc-L-脯氨醛的制备方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4213765A (en) | 1979-01-02 | 1980-07-22 | Union Carbide Corporation | Oxidative coal desulfurization using lime to regenerate alkali metal hydroxide from reaction product |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
EP0902782A1 (en) | 1996-04-23 | 1999-03-24 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
DK0966465T3 (da) | 1997-03-14 | 2003-10-20 | Vertex Pharma | Inhibitorer af IMPDH-enzymer |
CN1196687C (zh) | 1999-03-19 | 2005-04-13 | 沃泰克斯药物股份有限公司 | Impdh酶抑制剂 |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
WO2004050035A2 (en) * | 2002-12-03 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2680507A1 (en) | 2006-10-13 | 2008-04-24 | Xtl Biopharmaceuticals Ltd. | Compounds and methods for treatment of hcv |
EP2097405A2 (en) | 2006-11-21 | 2009-09-09 | Smithkline Beecham Corporation | Anti-viral compounds |
EP2250163B1 (en) | 2008-02-12 | 2012-03-28 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CA2715839C (en) | 2008-02-13 | 2014-12-09 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI454476B (zh) * | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作c型肝炎病毒抑制劑之巨環吲哚衍生物 |
US7906655B2 (en) * | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2745119A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
WO2010064100A1 (en) * | 2008-12-04 | 2010-06-10 | Intec Pharma Ltd. | Baclofen gastroretentive drug delivery system |
EP2393359A4 (en) * | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | COMPOUND DIBENZIMIDAZOLE DERIVATIVES |
TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US20120040977A1 (en) * | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
US8101643B2 (en) * | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
MX2011008982A (es) * | 2009-02-27 | 2011-09-15 | Enata Pharmaceuticals Inc | Inhibidores del virus de la hepatitis c. |
EP2857394A1 (en) | 2009-05-13 | 2015-04-08 | Gilead Pharmasset LLC | Antiviral compounds |
WO2010138791A1 (en) * | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
-
2010
- 2010-03-11 UA UAA201204598A patent/UA108211C2/uk unknown
- 2010-11-03 MX MX2012005178A patent/MX2012005178A/es not_active Application Discontinuation
- 2010-11-03 EA EA201290260A patent/EA022839B1/ru not_active IP Right Cessation
- 2010-11-03 US US13/508,186 patent/US9427428B2/en not_active Expired - Fee Related
- 2010-11-03 UY UY0001032997A patent/UY32997A/es unknown
- 2010-11-03 KR KR1020127014503A patent/KR20120091292A/ko not_active Application Discontinuation
- 2010-11-03 TW TW099137712A patent/TW201127378A/zh unknown
- 2010-11-03 BR BR112012010502A patent/BR112012010502A2/pt not_active IP Right Cessation
- 2010-11-03 CA CA2780034A patent/CA2780034C/en not_active Expired - Fee Related
- 2010-11-03 CN CN201080050509.7A patent/CN102741241B/zh not_active Expired - Fee Related
- 2010-11-03 EP EP10771766A patent/EP2496572A1/en not_active Withdrawn
- 2010-11-03 JP JP2012537376A patent/JP6005515B2/ja not_active Expired - Fee Related
- 2010-11-03 AU AU2010317085A patent/AU2010317085A1/en not_active Abandoned
- 2010-11-03 WO PCT/EP2010/066668 patent/WO2011054834A1/en active Application Filing
- 2010-11-03 AP AP2012006216A patent/AP2012006216A0/xx unknown
- 2010-11-04 AR ARP100104084A patent/AR078888A1/es not_active Application Discontinuation
-
2012
- 2012-04-05 IL IL219087A patent/IL219087A0/en unknown
- 2012-04-13 CO CO12061178A patent/CO6531445A2/es not_active Application Discontinuation
- 2012-05-03 ZA ZA2012/03205A patent/ZA201203205B/en unknown
- 2012-05-04 EC ECSP12011867 patent/ECSP12011867A/es unknown
- 2012-05-04 CL CL2012001176A patent/CL2012001176A1/es unknown
- 2012-06-04 CR CR20120302A patent/CR20120302A/es unknown
-
2013
- 2013-03-15 US US13/836,816 patent/US9433609B2/en not_active Expired - Fee Related
-
2016
- 2016-08-04 US US15/228,720 patent/US20160340344A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2012005178A (es) | 2012-06-08 |
EA022839B1 (ru) | 2016-03-31 |
CR20120302A (es) | 2012-10-25 |
AR078888A1 (es) | 2011-12-07 |
US20140107172A1 (en) | 2014-04-17 |
TW201127378A (en) | 2011-08-16 |
AU2010317085A1 (en) | 2012-05-10 |
US20160340344A1 (en) | 2016-11-24 |
JP2013510119A (ja) | 2013-03-21 |
CN102741241A (zh) | 2012-10-17 |
EA201290260A1 (ru) | 2013-12-30 |
CN102741241B (zh) | 2015-05-20 |
CO6531445A2 (es) | 2012-09-28 |
KR20120091292A (ko) | 2012-08-17 |
US9427428B2 (en) | 2016-08-30 |
IL219087A0 (en) | 2012-06-28 |
EP2496572A1 (en) | 2012-09-12 |
CL2012001176A1 (es) | 2012-08-31 |
JP6005515B2 (ja) | 2016-10-12 |
CA2780034C (en) | 2018-04-10 |
ZA201203205B (en) | 2014-10-29 |
CA2780034A1 (en) | 2011-05-12 |
US20120219594A1 (en) | 2012-08-30 |
US9433609B2 (en) | 2016-09-06 |
WO2011054834A1 (en) | 2011-05-12 |
ECSP12011867A (es) | 2012-10-30 |
UY32997A (es) | 2011-05-31 |
AP2012006216A0 (en) | 2012-04-30 |
UA108211C2 (uk) | 2015-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012010502A2 (pt) | derivados de benzimidazol-imidazol | |
LTC2170860I2 (lt) | Benzimidazolo dariniai | |
BR112012004969A2 (pt) | derivados de bis-benzimidazol | |
BR112012002662A2 (pt) | derivados de bis-benzimidazol | |
BR112012015868A2 (pt) | derivados de imidazolidinadiona | |
BRPI1013246A2 (pt) | derivados de benzofuralina | |
BR112012002828A2 (pt) | derivados de 5-fluorpirimidinona | |
BRPI1008749A2 (pt) | Derivados de benzodiazepina | |
ECSP12011999A (es) | Derivados benzamida sustituidos | |
BR112013013914A2 (pt) | derivados de hidantoína úteis como inibidores de kv3 | |
DK2283904T3 (da) | Komponentsystem | |
DK2308877T3 (da) | Imidazopyridin-2-on-derivater | |
BRPI1013844A2 (pt) | derivados de piridina-isoxazol | |
BRPI0817609A2 (pt) | Derivados de imidazol | |
DK2397480T3 (da) | Diazepindionderivat | |
BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
BR112013013695A2 (pt) | derivado de pirazol | |
BRPI1014454A2 (pt) | derivados de isoxazol-pirazol | |
DK2275414T3 (da) | Cyclopentylacrylamidderivat | |
BR112012016923A2 (pt) | Derivados de pirazol | |
BRPI0818855A2 (pt) | Derivados de imidazol | |
DK2387580T3 (da) | Deoxyactagardinderivater | |
BRPI0913234A2 (pt) | derivados de tiazolilpiperidina | |
ECSP12011977A (es) | Derivados de etinilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |